The claim is waiting. The bot is working.

Before a medical claim becomes money, someone often has to perform a remarkably ordinary act: open a website. Then another. Find the patient. Read the insurance response. Copy the answer somewhere else. Repeat. At a multi-location dermatology network described in Innobot Health’s case studies, insurance verification, claim-status checks, and pathology administration had become a daily occupation. More locations meant more clicking. The bottleneck was sitting between screens.

Innobot’s account of the dermatology project is refreshingly specific. One developer worked across three workflows over ten months. The resulting system processed approximately 100,000 transactions annually and returned 4,370 hours to the billing team. Those are company-reported results, rather than a promise about every practice. But they identify an interesting unit of progress: an insurance question answered, recorded, and removed from somebody’s morning.

A founder who knew the queue

Natasha Schlinkert founded Innobot in 2021 after a career in healthcare revenue cycle operations. Her complaint was practical. Experienced employees were spending their time retrieving information and typing it back into systems. In an October 2026 Stedi interview, she described still joining discovery calls and helping choose which processes to automate. The person selling the software remains involved in defining the work.

Her early founder pitch on Spark xyz shows a company selling developer time and consulting, with a team in Sri Lanka serving American clients. It also describes a plan to build a platform supported by subscriptions or transaction fees. That is a useful piece of company history: the product grew out of doing customer work, with the recurring platform business an explicit ambition.

“Bots themselves don’t break. The logic we feed them does.”Natasha Schlinkert, on Innobot’s company site

The last click matters

The company now calls its core platform IRIS, the Innobot Revenue Intelligence System. Its current website describes a loop: retrieve claim and encounter data, select the next action, route the work, execute it, and write the result into the existing system. Data can arrive through APIs, scheduled exports, or automation that retrieves reports as an employee would.

That final write-back matters. A dashboard can tell a manager that an authorization is missing. Someone still has to obtain it and record it. Innobot’s proposition includes that administrative completion: insurance details updated, payments posted, notes entered, claims resubmitted. The dashboard becomes a view of activity and financial outcomes, rather than another inbox that staff must empty.

The tools have memorable names. IVERA handles payer phone menus; ICHAT works with payer chatbots. IHELM schedules and monitors agents, while IFLOW captures desktop activity to discover what employees actually do. The platform page identifies Stedi as its clearinghouse connection and describes transaction-based licensing. The collection is a bid to own the journey from discovering repetitive work to running and watching it.

What ran out first was time

In Innobot’s national billing organization case study, growing workload had meant growing headcount. Staff moved between insurance websites, copied results, and struggled to see the total workload. The organization also faced an automation-platform transition. Innobot reports more than 654,000 automated billing tasks over twelve months, with 51,000 hours returned and $1.29 million in financial benefit across six tracked workflows.

A separate home-health and hospice case illustrates the timing problem. Coverage checks were happening at inconsistent points before visits, depending on how busy staff were. Innobot built parallel checks across insurers, standardized the results, and flagged coverage discrepancies. Its published figures reach 52,000 checks and 2,000 staff hours returned per month at peak production. The value is partly capacity; it is also knowing about a coverage problem while there is still time to respond.

The price is in the process

Cost is where the distinction between a case study and a quote becomes important. The dermatology project reports more than $110,000 in recurring annual value. That figure describes a benefit, not the customer’s invoice. The current platform follows transaction volume rather than seat count; the early business charged for developers and consulting. A prospective buyer needs the actual scope and commercial proposal to judge the arithmetic.

Implementation also depends on scope. Innobot’s about page offers a single-process engagement in three to five weeks. In her October Stedi interview, Schlinkert described implementation in eight to twelve weeks. Those are different published timeframes. A bounded eligibility workflow and a broader revenue cycle deployment should be evaluated as different projects, with their own acceptance criteria.

Its market sits between generic automation tools and labor-heavy billing operations. Hospitals, specialty practices, dental groups, and RCM companies bring different systems and payer rules. Innobot’s claimed advantage is the combination of revenue cycle knowledge and execution across those systems. A buyer is purchasing workflow expertise along with software. That puts the quality of process discovery at the center of the buying decision. A useful demonstration would follow a representative account all the way through, including the awkward cases, so staff can inspect the handoffs and compare the final record with their own standards.

Copy the sequence

The transferable idea is small enough to use without buying anything: watch the actual work, choose a repeated task, record its baseline, and define what completion means. Then count exceptions and verify the result in the system employees use. This is the practical implication of Innobot’s approach, rather than a guarantee that automation will pay for itself.

There are boundaries. Innobot’s public explanations keep medical judgment with people and route unresolved automation to an exception queue. Processes with ambiguous rules, unreliable inputs, or frequent changes need more review and maintenance. Its security page describes access controls, audit logging, and a business associate agreement with client contracts. For healthcare buyers, those operational details belong in the evaluation alongside speed.

A bot that moves a cursor is easy to picture. A dependable process is harder: it has to know what to do, recognize when it cannot, and leave a usable record. That is the useful question Innobot puts on the table. When the software finishes, is the claim still waiting for somebody?

Follow the work